The Senate Finance Committee unveiled a long-awaited drug-pricing bill, to be marked up Thursday (July 25), that includes monumental changes to drug-pricing policy in Medicare and Medicaid -- including restructuring the Part D benefit, imposing controversial inflationary rebates in Medicare Parts B and D, and raising the rebate cap in Medicaid.
NON-SUBSCRIBER OPTIONS
FREE TRIAL | NEWSSTAND
Providing a steady flow of breaking news, analysis, news briefs, document texts and more, all designed to ensure you have the best, most complete information available anywhere about what’s happening in drug pricing.
Log in to access this content.
Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on the coming Democrat-controlled House of Representatives, drug pricing reforms, Medicaid policy, FDA news and much more.
© 2002-2019. Inside Washington Publishers | Contact Us